BrainStorm Receives Additional $600,000 Non-Dilutive Grant From Israel's Office of the Chief Scientist

BrainStorm Receives Additional $600,000 Non-Dilutive Grant From Israel's Office 
of the Chief Scientist 
NEW YORK, NY and PETACH TIKVAH, ISRAEL -- (Marketwired) -- 02/25/14
--  BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading
developer of adult stem cell technologies for neurodegenerative
diseases, announced today that BrainStorm Cell Therapeutics Ltd. was
awarded an additional non-dilutive grant from Israel's Office of the
Chief Scientist (OCS) for the year 2014 in the amount of $600,000.
The grant is intended to support BrainStorm's clinical development
for its innovative stem cell therapy candidate NurOwn(TM). 
"We are thankful to the OCS for its ongoing support of our
activities. This additional non-dilutive grant is a boost to the
previous one of $800,000 recently awarded for 2014," said Mr. Chaim
Lebovits, BrainStorm's President and Principal Executive Officer. "We
see it as a further vote of confidence by the OCS in our company and
in our clinical programs," he added. 
The OCS has supported BrainStorm Cell Therapeutics Ltd. since 2007,
providing grants of a total of approximately $3.3 million until
today. The Company is required to pay royalties to the OCS, amounting
to 3% - 3.5% of revenues derived from sales of the products funded
with these grants, but only up to the amount equal to 100% of the
grants received plus LIBOR interest. 
About BrainStorm Cell Therapeutics, Inc.
 BrainStorm Cell
Therapeutics Inc. is a biotechnology company engaged in the
development of first-of-its-kind adult stem cell therapies derived
from autologous bone marrow cells for the treatment of
neurodegenerative diseases. The Company holds the rights to develop
and commercialize its NurOwn technology through an exclusive,
worldwide licensing agreement with Ramot, the technology transfer
company of Tel Aviv University. For more information, visit the
company's website at  
About the Office of the Chief Scientist
 The Office of the Chief
Scientist (OCS) in Israel's Ministry of Industry, Trade and Labor is
charged with execution of government policy for support of industrial
R&D. The goal of the OCS is to assist in the development of
technology in Israel as a means of fostering economic growth,
encouraging technological innovation and entrepreneurship, leveraging
Israel's scientific potential, enhancing the knowledge base of
industry in Israel, stimulating high value-added R&D and encouraging
R&D collaboration both nationally and internationally. 
Safe Harbor Statement
 Statements in this announcement other than
historical data and information constitute "forward-looking
statements" and involve risks and uncertainties that could cause
BrainStorm Cell Therapeutics Inc.'s actual results to differ
materially from those stated or implied by such forward-looking
statements. Terms and phrases such as "may", "should", "would",
"could", "will", "expect", "likely", "believe", "plan", "estimate",
"predict", "potential", and similar terms and phrases are intended to
identify these forward-looking statements. The potential risks and
uncertainties include, without limitation, risks associated with
BrainStorm's limited operating history, history of losses; minimal
working capital, dependence on its license to Ramot's technology;
ability to adequately protect the technology; dependence on key
executives and on its scientific consultants; ability to obtain
required regulatory approvals; and other factors detailed in
BrainStorm's annual report on Form 10-K and quarterly reports on Form
10-Q available at These factors should be
considered carefully, and readers should not place undue reliance on
BrainStorm's forward-looking statements. The forward-looking
statements contained in this press release are based on the beliefs,
expectations and opinions of management as of the date of this press
release. We do not assume any obligation to update forward-looking
statements to reflect actual results or assumptions if circumstances
or management's beliefs, expectations or opinions should change,
unless otherwise required by law. Although we believe that the
expectations reflected in the forward-looking statements are
reasonable, we cannot guarantee future results, levels of activity,
performance or achievements.  
Contact information:
BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI)
Mr. Chaim Lebovits, President
Phone: +972-3-9236384 
Press spacebar to pause and continue. Press esc to stop.